Phathom Pharmaceuticals has gained FDA approval for their new drug, vonoprazan, under the brand name Voquezna, as a treatment for non-erosive gastroesophageal reflux disease (GERD) in adults. Unlike traditional treatments like proton pump inhibitors, Voquezna works by blocking an enzyme system involved in the secretion of gastric acids. The drug has been shown to significantly reduce heartburn in patients who experience frequent symptoms. Phathom licensed the drug from Takeda Pharmaceutical and is exploring other indications for vonoprazan, including eosinophilic esophagitis. The company raised $181 million in an IPO to continue research and development of the drug.
Source link
Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients
